News articles about Repligen (NASDAQ:RGEN) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Repligen earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.8216860017009 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of analysts recently issued reports on the company. Zacks Investment Research downgraded Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, May 26th. BidaskClub upgraded Repligen from a “hold” rating to a “buy” rating in a research report on Monday, May 14th. Finally, TheStreet upgraded Repligen from a “c” rating to a “b-” rating in a research report on Tuesday, March 13th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Repligen presently has a consensus rating of “Buy” and an average target price of $44.88.

NASDAQ:RGEN opened at $44.68 on Wednesday. Repligen has a twelve month low of $29.56 and a twelve month high of $46.81. The firm has a market cap of $1.94 billion, a PE ratio of 64.75, a price-to-earnings-growth ratio of 2.96 and a beta of 0.90. The company has a quick ratio of 10.25, a current ratio of 12.22 and a debt-to-equity ratio of 0.17.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, May 8th. The biotechnology company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.02. Repligen had a return on equity of 6.06% and a net margin of 18.48%. The business had revenue of $44.80 million during the quarter, compared to the consensus estimate of $43.88 million. During the same period last year, the company earned $0.15 earnings per share. The business’s revenue for the quarter was up 46.4% compared to the same quarter last year. sell-side analysts anticipate that Repligen will post 0.7 earnings per share for the current year.

In other news, Director Thomas F. Ryan, Jr. sold 1,932 shares of Repligen stock in a transaction on Wednesday, June 6th. The stock was sold at an average price of $44.31, for a total transaction of $85,606.92. Following the completion of the sale, the director now directly owns 7,354 shares in the company, valued at $325,855.74. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Anthony Hunt sold 16,249 shares of Repligen stock in a transaction on Monday, May 21st. The stock was sold at an average price of $42.53, for a total value of $691,069.97. Following the sale, the chief executive officer now owns 243,144 shares of the company’s stock, valued at $10,340,914.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 303,531 shares of company stock valued at $12,561,406. Corporate insiders own 1.40% of the company’s stock.

About Repligen

Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor.

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.